Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 7, 2007, Pages 3230-3238

  Lajavardi, Laure ^a,b   Bochot, Amélie ^a   Camelo, Serge ^b   Goldenberg, Brigitte ^b   Naud, Marie Christine ^b   Behar Cohen, Francine ^b   Fattal, Elias ^a   De Kozak, Yvonne ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE; LIPOSOME; VASOACTIVE INTESTINAL POLYPEPTIDE; CYTOKINE; MACROGOL DERIVATIVE; MESSENGER RNA; PHOSPHATIDYLETHANOLAMINE; POLYETHYLENE GLYCOL DISTEAROYLPHOSPHATIDYLETHANOLAMINE; POLYETHYLENE GLYCOL-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CERVICAL LYMPH NODE; CILIARY BODY; CLINICAL ASSESSMENT; CONJUNCTIVA; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFLAMMATION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIPOSOMAL DELIVERY; MALE; MICROENVIRONMENT; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERA; UVEITIS; VITREOUS BODY; ANIMAL; AQUEOUS HUMOR; CONFOCAL MICROSCOPY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INJECTION; LEWIS RAT; LYMPH NODE; MACROPHAGE; METABOLISM; SALMONELLA TYPHIMURIUM;

ANIMALS; AQUEOUS HUMOR; CYTOKINES; DOWN-REGULATION; IMMUNOTHERAPY; INJECTIONS; LIPOPOLYSACCHARIDES; LIPOSOMES; LYMPH NODES; MACROPHAGES; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEUTROPHILS; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALMONELLA TYPHIMURIUM; UVEITIS; VASOACTIVE INTESTINAL PEPTIDE; VITREOUS BODY;

EID: 34548057327     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1305     Document Type: Article

References (72)

1. Rosenbaum JT, Becker MD, Smith JR. Immunologic ocular disease. In: Rich RR, ed. Clinical Immunology: Principles and Practice. 2nd ed. London: Harcourt Publishers; 2001:86.1-86.12.
2. Chang JH, McCluskey PJ, Wakefield D. Paediatric uveitis in Sydney (Letter). Clin Exp Ophthalmol. 2005;33:336; author reply, 336-337.
3. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286;611-613.
4. Ruiz-Moreno JM, Thillaye B, de Kozak Y. Retino-choroidal changes in endotoxin-induced uveitis in the rat. Ophthalmic Res. 1992;24: 162-168.
5. Yoshida M, Yoshimura N, Hangai M, Tanihara H, Honda Y. Interleukin-1 alpha, interleukin-1beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1994;35:1107-1113.
6. Tuaillon N, Shen DF, Berger RB, Lu B, Rollins BJ, Chan CC. MCP-1 expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2002;43:1493-1498.
7. Wakefield D, Montanaro A, McCluskey P. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 1991;36:223-232.
8. Feltkamp TE, Ringrose JH. Acute anterior uveitis and spondyloarthropathies. Curr Opin Rheumatol. 1998;10:314-318.
9. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336.
10. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
11. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96:7462-7466.
12. Kotter I, Zierhut M, Eckstein A, et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol. 2003;528:521-523.
13. Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211-2218.
14. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmunity. 1998; 11:255-264.
15. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol. 2002;20(suppl 28): S143-S145.
16. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006;33:231-237.
17. Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, Dunkel IJ. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol. 1998; 116:1209-1212.
18. Mao Y, Wu Z, Yang H, Lin S, Zheng J. Measurement of intraocular concentrations of etoposide after systemic and local administration. Yen Ko Hsueh Pao. 2004;20:178-180, 186.
19. Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin. 2000;40:205-220.
20. Halhal M, Renard G, Courtois Y, BenEzra D, Behar-Cohen F. Iontophoresis: from the lab to the bedside. Exp Eye Res. 2004;78: 751-757.
21. Lemaître C, Thillaye-Goldenberg B, Naud MC, de Kozak Y. The effects of intraocular injection of interleukin-13 on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2001;42:2022-2030.
22. Smith JR, Verwaerde C, Rolling F, et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther. 2005;16:1037-1046.
23. Bloquel C, Bejjani R, Bigey P, et al. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. FASEB J. 2006;20:389-391.
24. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001;29:2-6.
25. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002; 109:1709-1716.
26. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113: 1479-1496.
27. Fish G, Haller JA, Ho AC, et al. Eyetech Study Group: anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003;110:979-986.
28. Van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14:73-85.
29. Zeng S, Hu C, Wei H, et al. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophthalmology. 1993;100:1640-1644.
30. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11:1199-1206.
31. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to immunosuppressive activity of normal aqueous humor. J Immunol. 1994;153:1080-1086.
32. Martinez C, Delgado M, Pozo D, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998;63:591-601.
33. Delgado M, Munoz-Elias E, Gomariz R, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol. 1999;162:1707-1716.
34. Delgado M, Munoz-Elias E, Gomariz R, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages: subsequent effect on IFN synthesis by T cells. J Neuroimmunol. 1999; 96:167-181.
35. Delgado M, Munoz-Elias E, Gomariz R, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NFκB and IFN regulatory factor 1 activation. J Immunol. 1999;162:4685-4696.
36. Delgado M, Pozo D, Martinez C, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol. 1999;162:2358-2367.
37. Delgado M, Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol. 2001;167:966-975.
38. O'Dorisio MS, O'Dorisio TM, Wood CL, Bresnahan JC, Beattie MS, Campolito LB. Characterization of vasoactive intestinal peptide receptors in nervous and immune systems. Ann NY Acad Sci. 1988;527:257-281.
39. Blum AM, Mathew R, Cook GA, Metwali A, Felman R, Weinstock JV. Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells. J Neuroimmunol. 1992; 39:101-108.
40. Ottaway CA. Receptors for vasoactive intestinal peptide on murine lymphocytes turn over rapidly. J Neuroimmunol. 1992;38:241-253.
41. Pozo D, Delgado M, Martinez C, et al. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today. 2000;21:7-11.
42. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol. 2006;168:1179-1188.
43. + T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 2006;54:864-876.
44. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003;124:961-971.
45. Zhang MH, Hung L, Gery I. Vasoactive intestinal peptide (VIP) exacerbates endotoxin-induced uveitis (EIU) in mice. Curr Eye Res. 2000;21:913-917.
46. Keino K, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Usui M. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol. 2004;122:1179-1184.
47. Chen J, Vistica B, Wiggert B, Chan CC, Gery I. The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII mice. Ocul Immunol Inflamm. 2005;13:13-17.
48. Mody R, Tramontano A, Paul S. Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Int J Peptide Protein Res. 1994;44:441-447.
49. Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S. Stabilization of vasoactive intestinal peptide by lipids. J Pharmacol Exp Ther. 1998.285:753-758.
50. Séjourné F, Rubinstein I, Suzuki H, Alkan-Onyuksel H. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm Res. 1997;14: 362-365.
51. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466-468.
52. Pouvreau I, Zech J, Thillaye-Goldenberg B, Naud MC, Van Rooijen N, de Kozak Y. Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J Neuroimmunol. 1998;86:171-181.
53. Verwaerde C, Naud MC, Delanoye A, et al. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther. 2003;10:1970-1981.
54. Camelo S, Shanley AC, Voon AS, McMenamin PG. The distribution of antigen in lymphoid tissues following its injection into the anterior chamber of the rat eye. J Immunol. 2004;172:5388-5395.
55. Marie O, Thillaye-Goldenberg B, Naud MC, de Kozak Y. Inhibition of endotoxin-induced uveitis and potentiation of local TNF-alpha and interleukin-6 mRNA expression by interleukin-13. Invest Ophthalmol Vis Sci. 1999;40:2275-2282.
56. Thillaye-Goldenberg B, Goureau O, Naud MC, de Kozak Y. Delayed onset and decreased severity of experimental autoimmune uveoretinitis in mice lacking nitric oxide synthase type 2. J Neuroimmunol. 2000;110:31-44.
57. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci. 2002;43:253-259.
58. Akula S, Ma P, Peyman G, et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol. 1994;78:677-680.
59. Katayama T. The effect of vasoactive intestinal polypeptide (VIP) on ocular inflammation in rabbit ocular tissue. Nippon Ganka Gakkai Zasshi. 1989;93:16-21.
60. Bochot A, Couvreur P, Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res. 2000;19:131-147.
61. Kirby C, Clarke J, Gregoriadis G. Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980;186:591-598.
62. Allen TM, Cleland LG. Serum-induced leakage of liposome contents. Biochim Biophys Acta. 1980;597:418-426.
63. Fournier A, Saunders J, St-Pierre S. Synthesis, conformational studies and biological activities of VIP and related fragments. Peptides. 1984;5:169-177.
64. Onoue S, Matsumoto A, Nagano Y, et al. Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. Eur J Pharmacol. 2004;485:307-316.
65. Onoue S, Nagano Y, Tatsuno I, Uchida D, Kashimoto K. Receptor-binding specificity depending on N-terminal structure of VIP/PACAP. Biomed Res. 1999;20:219-231.
66. McMenamin PG, Crewe J. Endotoxin-induced uveitis: kinetics and phenotype of the inflammatory cell infiltrate and the response of the resident tissue macrophages and dendritic cells in the iris and ciliary body. Invest Ophthalmol Vis Sci. 1995;36:1949-1959.
67. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
68. De Kozak Y, Omri B, Smith JR, Naud MC, Thillaye-Goldenberg B, Crisanti P. Protein kinase Cζ regulates ocular inflammation and apoptosis in endotoxin-induced-uveitis. Am J Pathol. 2007;170: 1241-1257.
69. De Kozak Y, Andrieux K, Villarroya H, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol. 2004;34:3702-3712.
70. Hoffmann F, Zhang EP, Mueller A, et al. Contribution of lymphatic drainage system in corneal allograft rejection in mice. Graefes Arch Clin Exp Ophthalmol. 2001;239:850-858.
71. Camelo S, Shanley AC, Voon AS, McMenamin PG. An intravital and confocal microscopic study of the distribution of intracameral antigen in the aqueous outflow pathway and limbus of the rat eye. Exp Eye Res. 2004;79:455-464.
72. Camelo S, Kezic J, Shanley AC, Rigby P, McMenamin PG. Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest Ophthalmol Vis Sci. 2006;47:1039-1046.